文献速递毛发、甲与色素性疾病

儿童和成人斑秃患者抑郁和焦虑障碍及症状的患病率与比值比:系统综述与Meta分析

Prevalence and Odds of Depressive and Anxiety Disorders and Symptoms in Children and Adults With Alopecia Areata: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2023-01-01

该系统综述与Meta分析检索多个数据库至2020年8月1日,纳入37篇文章,区分斑秃患者的抑郁和焦虑障碍与症状。结果显示抑郁障碍患病率9%(OR 1.38),焦虑障碍患病率7%-17%(OR 1.51-1.69),均低于抑郁症状患病率37%(OR 2.70)和焦虑症状患病率34%(OR 3.07)。作者认为7%-17%的斑秃患者有需要精神科治疗的抑郁或焦虑障碍,超过三分之一患者有需监测的症状。

要点

  • 斑秃患者抑郁障碍患病率9%(OR 1.38),焦虑障碍患病率7%-17%(OR 1.51-1.69)。
  • 斑秃患者抑郁症状患病率37%(OR 2.70),焦虑症状患病率34%(OR 3.07)。
  • 7%-17%的斑秃患者有需要精神科治疗的抑郁或焦虑障碍。

核心结论

  • 区分障碍与症状的分析显示,7%-17%的斑秃患者有需要精神科治疗(包括特定药物治疗)的抑郁或焦虑障碍。
  • 超过三分之一的斑秃患者有抑郁或焦虑症状,这些症状是警示信号,需要监测,因其可能发展为障碍。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、ScienceDirect、Cochrane Library、Embase和PsycINFO数据库自建库至2020年8月1日。
  • 共纳入37篇文章,其中29篇关于抑郁,26篇关于焦虑;采用观察性研究Meta分析报告指南(MOOSE),使用随机效应模型计算合并患病率,并采用Meta回归分析患病率变异与Study特征的关系。

主要发现

  • 斑秃患者抑郁障碍患病率为9%(OR 1.38),焦虑障碍患病率为7%-17%(OR 1.51-1.69)。
  • 斑秃患者抑郁症状患病率为37%(OR 2.70),焦虑症状患病率为34%(OR 3.07)。
  • Meta回归显示患病率变异主要与Study间方法学差异相关。

临床怎么用

  • 作者认为7%-17%的斑秃患者有需要精神科治疗(包括特定药物治疗)的抑郁或焦虑障碍。
  • 作者认为超过三分之一的斑秃患者有需要监测的抑郁或焦虑症状,因其可能发展为障碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Two recent meta-analyses reported a high prevalence of both anxiety and depression in patients with alopecia areata (AA), as well as a positive association of AA with anxiety and depression, without distinguishing between disorders and symptoms. Yet, depression and anxiety can manifest either as symptoms identified in questionnaires or as specific diagnoses defined by Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision criteria. OBJECTIVE: To perform a large meta-analysis separating the prevalence of depressive and anxiety disorders from that of depressive and anxiety symptoms in patients with AA. DATA SOURCES: PubMed, ScienceDirect, the Cochrane Library, Embase, and PsycINFO databases were searched from inception through August 1, 2020. STUDY SELECTION: Studies that contained data on the prevalence of depressive or anxiety disorders or symptoms were included. DATA EXTRACTION AND SYNTHESIS: The Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines were used. Pooled prevalence was calculated with a random effects model meta-analysis that took into account between- and within-study variability. Meta-regressions were used to study the association between variations in prevalence and study characteristics. MAIN OUTCOMES AND MEASURES: The prevalence of depressive and anxiety disorders and symptoms in patients with AA. RESULTS: Thirty-seven articles (29 on depression and 26 on anxiety) that met the inclusion criteria were identified. By distinguishing between disorders and symptoms, the prevalence of both depressive disorders (9%) and unspecified anxiety disorders (13%) in patients with AA was shown to be greater than that in the general population. The prevalence and odds ratio (OR) of depressive disorders (prevalence, 9%; OR, 1.38) and anxiety disorders of which each category had been specifically studied (prevalence, 7%-17%; OR, 1.51-1.69) were markedly lower than that of depressive symptoms (prevalence, 37%; OR, 2.70) and anxiety symptoms (prevalence, 34%; OR, 3.07). Meta-regressions showed that variations in prevalence were mainly associated with methodological differences between studies. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, the separate analyses showed that 7% to 17% of patients with AA had depressive or anxiety disorders that require psychiatric care, including specific medication. Additionally, more than one-third of patients had symptoms that are warning signs and that need monitoring because they can develop into disorders.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lauron S, Plasse C, Vaysset M, et al. Prevalence and Odds of Depressive and Anxiety Disorders and Symptoms in Children and Adults With Alopecia Areata: A Systematic Review and Meta-analysis. JAMA Dermatol. 2023. PMID: 36696123. doi:10.1001/jamadermatol.2022.6085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。